Ibrutinib holds promise for patients with 17p deletion CLL
Mené sur 144 patients atteints d'une leucémie lymphoïde chronique récidivante ou réfractaire avec délétion 17p, cet essai international de phase II évalue l'efficacité, du point de vue de la réponse globale, et la toxicité de l'ibrutinib
The heterogeneity of the disease course and outcome in patients with chronic lymphocytic leukaemia is well known in haematological oncology. This heterogeneity is exemplified by patients who carry aberrations in the TP53 gene, namely deletion 17p (del17p) or mutations in this gene. These patients generally have an aggressive disease and diminished life expectancy, mainly because of a paucity of treatment options owing to the inefficacy of chemoimmunotherapy-based regimens. Allogeneic transplantation may be the only viable treatment option for these patients, although this is often not possible because this disease is more common in older patients who are unable to undergo such procedure.
The Lancet Oncology , commentaire, 2015